Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Joaquin Bellmunt Molins, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Joaquin Bellmunt Molins and David McDermott.
Joaquin Bellmunt Molins
Connection Strength
0.159
David McDermott
  1. Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw. 2016 07; 14(7):820-4.
    View in: PubMed
    Score: 0.042
  2. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
    View in: PubMed
    Score: 0.041
  3. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 05 15; 22(10):2445-2452.
    View in: PubMed
    Score: 0.041
  4. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol. 2014 Jan; 44(1):5-16.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.